## Short-term interferon treatment of serum hepatitis B e anti- Chronic infection with precore mutant strains of hepatitis B virus (HBV) resulting in infection with hepatitis B surface gen (HBeAg)-negative carriers with serum hepatitis B virus (HBV) DNA and histological features of chronic hepatit
A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum
✍ Scribed by P Lampertico; E Del Ninno; A Manzin; MF Donato; MG Rumi; G Lunghi; A Morabito; M Clementi; M Colombo
- Book ID
- 118686774
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 201 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
ment for anti-HBe-positive chronic hepatitis. The benefit It has recently been shown that thymosin-a 1 (T-a 1 ), a of this agent in producing long-term inhibition of HBV synthetic polypeptide of thymic origin, is able to proreplication must be confirmed by future trials. (HEPAmote disease remission
This study was undertaken to compare the early antiviral activity and viral kinetic profiles of entecavir (ETV) versus adefovir (ADV) in hepatitis B e antigen positive nucleoside-naïve adults with chronic hepatitis B (CHB). Sixty-nine nucleoside-naïve CHB patients with baseline HBV DNA of 10(8) copi
To study whether interferon (IFN) ␣ and ribavirin combination therapy has a beneficial effect for hepatitis B e antigen (HBeAg)-positive chronic hepatitis B, we enrolled 119 such patients in a randomized study. Fifty-nine patients received 5 million units of IFN-␣2b daily for 4 weeks followed by 5 m